{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "15",
                "@timestamp": "2022-09-15T17:13:42.000042-04:00",
                "@year": "2022",
                "@month": "09"
            },
            "ait:date-sort": {
                "@day": "23",
                "@year": "2020",
                "@month": "08"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": [
                {"xocs:funding-agency-matched-string": "National Comprehensive Cancer Center"},
                {
                    "xocs:funding-agency-matched-string": "Conquer Cancer Foundation of ASCO",
                    "xocs:funding-agency-acronym": "CCF",
                    "xocs:funding-agency": "Conquer Cancer Foundation",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100000982",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "American Society of Hematology",
                    "xocs:funding-agency-acronym": "ASH",
                    "xocs:funding-agency": "American Society of Hematology",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100001422",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Leukemia and Lymphoma Society",
                    "xocs:funding-agency-acronym": "LLS",
                    "xocs:funding-agency": "Leukemia and Lymphoma Society",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100005189",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "Geoffrey Beene Cancer Foundation",
                    "xocs:funding-agency": "Geoffrey Beene Cancer Research Center",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100009859",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                }
            ],
            "xocs:funding-addon-generated-timestamp": "2021-06-04T10:09:50.281Z",
            "xocs:funding-text": "KW receives salary support from Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center. JHP receives funding from the Conquer Cancer Foundation of ASCO, a Leukemia and Lymphoma Society Career Development Grant, the Geoffrey Beene Cancer Foundation, a National Comprehensive Cancer Center Young Investigator Award, and an American Society of Hematology Scholar Junior Faculty Award. KW receives salary support from Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.",
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "109501192"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2005381276-d0bfd002ed7fc63c086d5d105db34b75",
                            "ce:source-text": "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA,;",
                            "@dptid": "109501192"
                        },
                        "author": [{
                            "ce:given-name": "Kitsada",
                            "preferred-name": {
                                "ce:given-name": "Kitsada",
                                "ce:initials": "K.",
                                "ce:surname": "Wudhikarn",
                                "ce:indexed-name": "Wudhikarn K."
                            },
                            "@author-instance-id": "2005381276-d7a25d8a02d7e8516a087bd5557b10ae",
                            "@seq": "1",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wudhikarn",
                            "@auid": "37091810400",
                            "@orcid": "0000-0001-9528-8681",
                            "ce:indexed-name": "Wudhikarn K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60028190",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Research Unit in Translational Hematology and Division of Hematology"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": {
                                "@afid": "60028190",
                                "@dptid": "113019942"
                            },
                            "@affiliation-instance-id": "2005381276-55a81ae2fee2c338c68169bd53dc873e",
                            "ce:source-text": "Department of Medicine, Research Unit in Translational Hematology and Division of Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand,;",
                            "@dptid": "113019942"
                        },
                        "author": [{
                            "ce:given-name": "Kitsada",
                            "preferred-name": {
                                "ce:given-name": "Kitsada",
                                "ce:initials": "K.",
                                "ce:surname": "Wudhikarn",
                                "ce:indexed-name": "Wudhikarn K."
                            },
                            "@author-instance-id": "2005381276-d7a25d8a02d7e8516a087bd5557b10ae",
                            "@seq": "1",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wudhikarn",
                            "@auid": "37091810400",
                            "ce:indexed-name": "Wudhikarn K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60009343",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Leukemia Service"},
                                {"$": "Division of Hematologic Malignancy"},
                                {"$": "Memorial Sloan Kettering Cancer Center"}
                            ],
                            "affiliation-id": {
                                "@afid": "60009343",
                                "@dptid": "103509285"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2005381276-05614f120459c02f4caa89163f8e4ca2",
                            "ce:source-text": "Leukemia Service, Division of Hematologic Malignancy, Memorial Sloan Kettering Cancer Center, New York, NY, USA,;",
                            "@dptid": "103509285"
                        },
                        "author": [{
                            "ce:given-name": "Jae H.",
                            "preferred-name": {
                                "ce:given-name": "Jae H.",
                                "ce:initials": "J.H.",
                                "ce:surname": "Park",
                                "ce:indexed-name": "Park J.H."
                            },
                            "@author-instance-id": "2005381276-3d3e96c01423dc9c695d7dbfcd6c2706",
                            "@seq": "2",
                            "ce:initials": "J.H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Park",
                            "@auid": "45561459900",
                            "ce:indexed-name": "Park J.H."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "108088405",
                            "@country": "usa",
                            "city": "New York",
                            "organization": [
                                {"$": "Department of Medicine"},
                                {"$": "Weil Cornel College of Medicine"}
                            ],
                            "affiliation-id": {
                                "@afid": "108088405",
                                "@dptid": "114113368"
                            },
                            "state": "NY",
                            "@affiliation-instance-id": "2005381276-b9e1fd1d9d7d40d729a775777edb3a27",
                            "ce:source-text": "Department of Medicine, Weil Cornel College of Medicine, New York, NY, USA",
                            "@dptid": "114113368"
                        },
                        "author": [{
                            "ce:given-name": "Jae H.",
                            "preferred-name": {
                                "ce:given-name": "Jae H.",
                                "ce:initials": "J.H.",
                                "ce:surname": "Park",
                                "ce:indexed-name": "Park J.H."
                            },
                            "@author-instance-id": "2005381276-3d3e96c01423dc9c695d7dbfcd6c2706",
                            "@seq": "2",
                            "ce:initials": "J.H.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Park",
                            "@auid": "45561459900",
                            "ce:indexed-name": "Park J.H."
                        }]
                    }
                ],
                "citation-title": "Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice",
                "abstracts": "© 2020 Informa UK Limited, trading as Taylor & Francis Group.Over the past recent years, CD19-targeted chimeric antigen receptor T (CAR T) cell has transformed the treatment of relapsed/refractory (R/R) B lymphoid hematologic malignancy. CAR T cell therapy elicits an excellent anti-tumor effect and extends long-term disease-free remission in these difficult-to-treat patients. Notwithstanding, despite the impressive anti-tumor efficacy, some patients fail to attain clinical response or relapse after extended follow-up. The success of CAR T cell therapy involves complex interplays between host, tumor, and CAR T cell-associated arrays. Researchers have extensively explored potential predictive biomarkers for response to CAR T cell therapy. Ability to identify clinical and biological factors associated with improved response will help determine appropriate patients for CAR T cell treatment and enhance the clinical outcome of this novel therapeutic approach.",
                "correspondence": {
                    "affiliation": {
                        "country": "United States",
                        "postal-code": "10065",
                        "@country": "usa",
                        "city": "New York",
                        "organization": [
                            {"$": "Leukemia Service"},
                            {"$": "Division of Hematologic Malignancy"},
                            {"$": "Memorial Sloan Kettering Cancer Center"}
                        ],
                        "state": "NY",
                        "ce:source-text": "CONTACT Jae H. Park, parkj6@mskcc.org, Leukemia Service, Division of Hematologic Malignancy, Memorial Sloan Kettering Cancer Center, New York, 10065, NY, USA"
                    },
                    "person": {
                        "ce:given-name": "Jae H.",
                        "ce:initials": "J.H.",
                        "ce:surname": "Park",
                        "ce:indexed-name": "Park J.H."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "Chimeric antigen receptor T cell (CAR T cell)",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "immunotherapy",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "leukemia",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "lymphoma",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "re"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "https://www.tandfonline.com/loi/ilal20",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "Leukemia and Lymphoma",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "61",
                            "@issue": "10"
                        },
                        "pagerange": {
                            "@first": "2324",
                            "@last": "2334"
                        }
                    },
                    "@type": "j",
                    "sourcetitle": "Leukemia and Lymphoma",
                    "publicationdate": {
                        "month": "08",
                        "year": "2020",
                        "date-text": {
                            "@xfab-added": "true",
                            "$": "23 August 2020"
                        },
                        "day": "23"
                    },
                    "codencode": "LELYE",
                    "sourcetitle-abbrev": "Leuk. Lymphoma",
                    "@country": "gbr",
                    "issn": [
                        {
                            "$": "10292403",
                            "@type": "electronic"
                        },
                        {
                            "$": "10428194",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2020"},
                    "publisher": {
                        "publishername": "Taylor and Francis Ltd.",
                        "ce:e-address": {
                            "$": "michael.wagreich@univie.ac.at",
                            "@type": "email"
                        }
                    },
                    "@srcid": "26016"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "CABSCLASS",
                            "classification": [
                                {
                                    "classification-code": "86.9.1.2",
                                    "classification-description": "IMMUNOLOGY AND INFECTIOUS DISEASES; TUMOUR IMMUNOLOGY; Neoplasia of Immune System; Human studies"
                                },
                                {
                                    "classification-code": "86.9.3.4",
                                    "classification-description": "IMMUNOLOGY AND INFECTIOUS DISEASES; TUMOUR IMMUNOLOGY; Tumour Immunotherapy; Adoptive"
                                },
                                {
                                    "classification-code": "87.4.3.4",
                                    "classification-description": "CANCER RESEARCH; TREATMENT; Immunotherapy; Adoptive"
                                },
                                {
                                    "classification-code": "87.5.26",
                                    "classification-description": "CANCER RESEARCH; CLINICAL INVESTIGATIONS BY ORGAN SITE; Haematologic Malignancies"
                                }
                            ]
                        },
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "16",
                                    "classification-description": "Cancer"
                                },
                                {
                                    "classification-code": "25",
                                    "classification-description": "Hematology"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": [
                                {"$": "2720"},
                                {"$": "2730"},
                                {"$": "1306"}
                            ]
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": [
                                {"$": "MEDI"},
                                {"$": "BIOC"}
                            ]
                        }
                    ]},
                    "chemicalgroup": {"chemicals": {
                        "@source": "nlm",
                        "chemical": [
                            {"chemical-name": "Antigens, CD19"},
                            {"chemical-name": "Receptors, Antigen, T-Cell"},
                            {"chemical-name": "Receptors, Chimeric Antigen"}
                        ]
                    }}
                },
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "KW receives salary support from Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center. JHP receives funding from the Conquer Cancer Foundation of ASCO, a Leukemia and Lymphoma Society Career Development Grant, the Geoffrey Beene Cancer Foundation, a National Comprehensive Cancer Center Young Investigator Award, and an American Society of Hematology Scholar Junior Faculty Award. KW receives salary support from Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.",
                        "@xml:lang": "eng"
                    }
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2020 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "In-Data-Review",
                "dbcollection": [
                    {"$": "CABS"},
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "28",
                    "@timestamp": "BST 09:30:56",
                    "@year": "2020",
                    "@month": "10"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2005381276",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "632048966",
                            "@idtype": "associatedPUI"
                        },
                        {
                            "$": "2020223816",
                            "@idtype": "CABS"
                        },
                        {
                            "$": "926517059",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20200531851",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "32522059",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20201377846",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20202362744",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20200008783731",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85087032230",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85087032230",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "632048966",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "76765899",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1080/10428194.2020.1761967"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "84",
                "reference": [
                    {
                        "ref-fulltext": "Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032\u20132041.",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2012"},
                            "ref-title": {"ref-titletext": "Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0001",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84866094086",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "120",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "2032",
                                    "@last": "2041"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Gokbuget",
                                        "ce:indexed-name": "Gokbuget N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Stanze",
                                        "ce:indexed-name": "Stanze D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Beck",
                                        "ce:indexed-name": "Beck J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032\u20132041."
                    },
                    {
                        "ref-fulltext": "Gokbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524\u20131533.",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0002",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85002157898",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "101",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "1524",
                                    "@last": "1533"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Gokbuget",
                                        "ce:indexed-name": "Gokbuget N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Dombret",
                                        "ce:indexed-name": "Dombret H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Ribera",
                                        "ce:indexed-name": "Ribera J.M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Haematologica"
                        },
                        "ce:source-text": "Gokbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524\u20131533."
                    },
                    {
                        "ref-fulltext": "Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20131808.",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0003",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85032021614",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "130",
                                    "@issue": "16"
                                },
                                "pagerange": {
                                    "@first": "1800",
                                    "@last": "1808"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Crump",
                                        "ce:indexed-name": "Crump M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "U.",
                                        "@_fa": "true",
                                        "ce:surname": "Farooq",
                                        "ce:indexed-name": "Farooq U."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20131808."
                    },
                    {
                        "ref-fulltext": "Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u2013448.",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0004",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85041428116",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "378",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "439",
                                    "@last": "448"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Maude",
                                        "ce:indexed-name": "Maude S.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Laetsch",
                                        "ce:indexed-name": "Laetsch T.W."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Buechner",
                                        "ce:indexed-name": "Buechner J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u2013448."
                    },
                    {
                        "ref-fulltext": "Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u20132544.",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0005",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85040170618",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "377",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "2531",
                                    "@last": "2544"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Bartlett",
                                        "ce:indexed-name": "Bartlett N.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u20132544."
                    },
                    {
                        "ref-fulltext": "Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0006",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058995720",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "380",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "45",
                                    "@last": "56"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Schuster",
                                        "ce:indexed-name": "Schuster S.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Bishop",
                                        "ce:indexed-name": "Bishop M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tam",
                                        "ce:indexed-name": "Tam C.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356."
                    },
                    {
                        "ref-fulltext": "Tran E, Longo DL, Urba WJ. A milestone for CAR T cells. N Engl J Med. 2017;377(26):2593\u20132596.",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "A milestone for CAR T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0007",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85039776836",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "377",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "2593",
                                    "@last": "2596"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "E.",
                                    "@_fa": "true",
                                    "ce:surname": "Tran",
                                    "ce:indexed-name": "Tran E."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "D.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Longo",
                                    "ce:indexed-name": "Longo D.L."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "W.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Urba",
                                    "ce:indexed-name": "Urba W.J."
                                }
                            ]},
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Tran E, Longo DL, Urba WJ. A milestone for CAR T cells. N Engl J Med. 2017;377(26):2593\u20132596."
                    },
                    {
                        "ref-fulltext": "Nastoupil LJ, Jain MD, Spiegel JY, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. Blood. 2018;132(1):91\u201391.",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0008",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85060008763",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "132",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "91"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Nastoupil",
                                        "ce:indexed-name": "Nastoupil L.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Jain",
                                        "ce:indexed-name": "Jain M.D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Spiegel",
                                        "ce:indexed-name": "Spiegel J.Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Nastoupil LJ, Jain MD, Spiegel JY, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. Blood. 2018;132(1):91\u201391."
                    },
                    {
                        "ref-fulltext": "Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31\u201342.",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0009",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85059501669",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "31",
                                    "@last": "42"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ghobadi",
                                        "ce:indexed-name": "Ghobadi A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet Oncol"
                        },
                        "ce:source-text": "Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31\u201342."
                    },
                    {
                        "ref-fulltext": "Neelapu SS, Ghobadi A, Jacobson CA, et al. 2-year follow-up and high-risk cubset analysis of zuma-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2019;25(3):S65.",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "2-year follow-up and high-risk cubset analysis of zuma-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0010",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85065057009",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "S65"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Neelapu",
                                        "ce:indexed-name": "Neelapu S.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ghobadi",
                                        "ce:indexed-name": "Ghobadi A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Neelapu SS, Ghobadi A, Jacobson CA, et al. 2-year follow-up and high-risk cubset analysis of zuma-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2019;25(3):S65."
                    },
                    {
                        "ref-fulltext": "Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361\u20132368.",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0011",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85077295034",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "2361",
                                    "@last": "2368"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Curran",
                                        "ce:indexed-name": "Curran K.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Margossian",
                                        "ce:indexed-name": "Margossian S.P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Kernan",
                                        "ce:indexed-name": "Kernan N.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Curran KJ, Margossian SP, Kernan NA, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019;134(26):2361\u20132368."
                    },
                    {
                        "ref-fulltext": "Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u2013528.",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0012",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84923019006",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "385",
                                    "@issue": "9967"
                                },
                                "pagerange": {
                                    "@first": "517",
                                    "@last": "528"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee D.W."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Kochenderfer",
                                        "ce:indexed-name": "Kochenderfer J.N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Stetler-Stevenson",
                                        "ce:indexed-name": "Stetler-Stevenson M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u2013528."
                    },
                    {
                        "ref-fulltext": "Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u2013459.",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0013",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85041377767",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "378",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "449",
                                    "@last": "459"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Park",
                                        "ce:indexed-name": "Park J.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Rivière",
                                        "ce:indexed-name": "Riviere I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Gonen",
                                        "ce:indexed-name": "Gonen M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u2013459."
                    },
                    {
                        "ref-fulltext": "Frey NV, Shaw PA, Hexner EO, et al. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2020;38(5):415\u2013422.",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0014",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85079075868",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "38",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "415",
                                    "@last": "422"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Frey",
                                        "ce:indexed-name": "Frey N.V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Shaw",
                                        "ce:indexed-name": "Shaw P.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.O.",
                                        "@_fa": "true",
                                        "ce:surname": "Hexner",
                                        "ce:indexed-name": "Hexner E.O."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Frey NV, Shaw PA, Hexner EO, et al. Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2020;38(5):415\u2013422."
                    },
                    {
                        "ref-fulltext": "Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u20133330.",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Toxicities of chimeric antigen receptor T cells: recognition and management"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0015",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84977477922",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "127",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "3321",
                                    "@last": "3330"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.N.",
                                    "@_fa": "true",
                                    "ce:surname": "Brudno",
                                    "ce:indexed-name": "Brudno J.N."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.N.",
                                    "@_fa": "true",
                                    "ce:surname": "Kochenderfer",
                                    "ce:indexed-name": "Kochenderfer J.N."
                                }
                            ]},
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u20133330."
                    },
                    {
                        "ref-fulltext": "Santomasso B, Bachier C, Westin J, et al. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39(39):433\u2013444.",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0016",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072734814",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "39",
                                    "@issue": "39"
                                },
                                "pagerange": {
                                    "@first": "433",
                                    "@last": "444"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Santomasso",
                                        "ce:indexed-name": "Santomasso B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Bachier",
                                        "ce:indexed-name": "Bachier C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Westin",
                                        "ce:indexed-name": "Westin J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Am Soc Clin Oncol Educ Book"
                        },
                        "ce:source-text": "Santomasso B, Bachier C, Westin J, et al. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39(39):433\u2013444."
                    },
                    {
                        "ref-fulltext": "Lesch S, Benmebarek MR, Cadilha BL, et al. Determinants of response and resistance to CAR T cell therapy. Semin Cancer Biol. 2019. doi:10.1016/j.semcancer.2019.11.004",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Determinants of response and resistance to CAR T cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "10.1016/j.semcancer.2019.11.004",
                                    "@idtype": "DOI"
                                },
                                {
                                    "$": "CIT0017",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075445903",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Lesch",
                                        "ce:indexed-name": "Lesch S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Benmebarek",
                                        "ce:indexed-name": "Benmebarek M.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Cadilha",
                                        "ce:indexed-name": "Cadilha B.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Semin Cancer Biol"
                        },
                        "ce:source-text": "Lesch S, Benmebarek MR, Cadilha BL, et al. Determinants of response and resistance to CAR T cell therapy. Semin Cancer Biol. 2019. doi:10.1016/j.semcancer.2019.11.004"
                    },
                    {
                        "ref-fulltext": "Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139\u2013303ra139.",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0018",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84940881287",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "303"
                                },
                                "pagerange": {"@first": "303ra139"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Porter",
                                        "ce:indexed-name": "Porter D.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "W.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Hwang",
                                        "ce:indexed-name": "Hwang W.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Frey",
                                        "ce:indexed-name": "Frey N.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139\u2013303ra139."
                    },
                    {
                        "ref-fulltext": "Bishop MR, Maziarz RT, Waller EK, et al. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. 2019;3(14):2230\u20132236.",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0019",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85069681114",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "14"
                                },
                                "pagerange": {
                                    "@first": "2230",
                                    "@last": "2236"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Bishop",
                                        "ce:indexed-name": "Bishop M.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Maziarz",
                                        "ce:indexed-name": "Maziarz R.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Waller",
                                        "ce:indexed-name": "Waller E.K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Bishop MR, Maziarz RT, Waller EK, et al. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. 2019;3(14):2230\u20132236."
                    },
                    {
                        "ref-fulltext": "Abramson JS, Palomba ML, Gordon LI, et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood. 2019;134(1):241\u2013241.",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0020",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85079068010",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "241"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Abramson",
                                        "ce:indexed-name": "Abramson J.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Palomba",
                                        "ce:indexed-name": "Palomba M.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Gordon",
                                        "ce:indexed-name": "Gordon L.I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Abramson JS, Palomba ML, Gordon LI, et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood. 2019;134(1):241\u2013241."
                    },
                    {
                        "ref-fulltext": "Maziarz RT, Schuster SJ, Ericson SG, et al. Cytokine release syndrome and neurotoxicity by baseline tumor burden in adults with relapsed or refractory diffuse large b-cell lymphoma treated with tisagenlecleucel. Hematol Oncol. 2019;37(S2):307\u2013307.",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Cytokine release syndrome and neurotoxicity by baseline tumor burden in adults with relapsed or refractory diffuse large b-cell lymphoma treated with tisagenlecleucel"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0021",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85082186010",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "37",
                                    "@issue": "S2"
                                },
                                "pagerange": {"@first": "307"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Maziarz",
                                        "ce:indexed-name": "Maziarz R.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Schuster",
                                        "ce:indexed-name": "Schuster S.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Ericson",
                                        "ce:indexed-name": "Ericson S.G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Hematol Oncol"
                        },
                        "ce:source-text": "Maziarz RT, Schuster SJ, Ericson SG, et al. Cytokine release syndrome and neurotoxicity by baseline tumor burden in adults with relapsed or refractory diffuse large b-cell lymphoma treated with tisagenlecleucel. Hematol Oncol. 2019;37(S2):307\u2013307."
                    },
                    {
                        "ref-fulltext": "Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u20132306.",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0022",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85034805472",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "130",
                                    "@issue": "21"
                                },
                                "pagerange": {
                                    "@first": "2295",
                                    "@last": "2306"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u20132306."
                    },
                    {
                        "ref-fulltext": "Hay KA, Gauthier J, Hirayama AV, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u20131663.",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0023",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85064806676",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "133",
                                    "@issue": "15"
                                },
                                "pagerange": {
                                    "@first": "1652",
                                    "@last": "1663"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gauthier",
                                        "ce:indexed-name": "Gauthier J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Hirayama",
                                        "ce:indexed-name": "Hirayama A.V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Hay KA, Gauthier J, Hirayama AV, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u20131663."
                    },
                    {
                        "ref-fulltext": "Locke FL, Ghobadi A, Jacobson CA, et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. J Clin Oncol. 2018;36(15):3003\u20133003.",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0024",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052989886",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "15"
                                },
                                "pagerange": {"@first": "3003"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Locke",
                                        "ce:indexed-name": "Locke F.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ghobadi",
                                        "ce:indexed-name": "Ghobadi A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Jacobson",
                                        "ce:indexed-name": "Jacobson C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Locke FL, Ghobadi A, Jacobson CA, et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. J Clin Oncol. 2018;36(15):3003\u20133003."
                    },
                    {
                        "ref-fulltext": "Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u20133068.",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0025",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84903462466",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "32",
                                    "@issue": "27"
                                },
                                "pagerange": {
                                    "@first": "3059",
                                    "@last": "3068"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Cheson",
                                        "ce:indexed-name": "Cheson B.D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Fisher",
                                        "ce:indexed-name": "Fisher R.I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Barrington",
                                        "ce:indexed-name": "Barrington S.F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u20133068."
                    },
                    {
                        "ref-fulltext": "Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1876\u20131887.",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0026",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85065170101",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "133",
                                    "@issue": "17"
                                },
                                "pagerange": {
                                    "@first": "1876",
                                    "@last": "1887"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Hirayama",
                                        "ce:indexed-name": "Hirayama A.V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gauthier",
                                        "ce:indexed-name": "Gauthier J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hay",
                                        "ce:indexed-name": "Hay K.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1876\u20131887."
                    },
                    {
                        "ref-fulltext": "Watanabe K, Terakura S, Martens AC, et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells. J Immunol. 2015;194(3):911\u2013920.",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0027",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84921473544",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "194",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "911",
                                    "@last": "920"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Watanabe",
                                        "ce:indexed-name": "Watanabe K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Terakura",
                                        "ce:indexed-name": "Terakura S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Martens",
                                        "ce:indexed-name": "Martens A.C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Immunol"
                        },
                        "ce:source-text": "Watanabe K, Terakura S, Martens AC, et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells. J Immunol. 2015;194(3):911\u2013920."
                    },
                    {
                        "ref-fulltext": "Watanabe K, Kuramitsu S, Posey AD, et al. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T. Cell Biol Front Immunol. 2018;9:2486.",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0028",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85055840701",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "9"},
                                "pagerange": {"@first": "2486"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Watanabe",
                                        "ce:indexed-name": "Watanabe K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Kuramitsu",
                                        "ce:indexed-name": "Kuramitsu S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Posey",
                                        "ce:indexed-name": "Posey A.D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Cell Biol Front Immunol"
                        },
                        "ce:source-text": "Watanabe K, Kuramitsu S, Posey AD, et al. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T. Cell Biol Front Immunol. 2018;9:2486."
                    },
                    {
                        "ref-fulltext": "Pillai V, Muralidharan K, Meng W, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539\u20133549.",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0029",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85076344065",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "22"
                                },
                                "pagerange": {
                                    "@first": "3539",
                                    "@last": "3549"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Pillai",
                                        "ce:indexed-name": "Pillai V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Muralidharan",
                                        "ce:indexed-name": "Muralidharan K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Meng",
                                        "ce:indexed-name": "Meng W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Pillai V, Muralidharan K, Meng W, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539\u20133549."
                    },
                    {
                        "ref-fulltext": "Pillai V, Rosenthal J, Muralidharan K, et al. Correlation of pre-CAR CD19 expression with responses and relapses after CAR T cell therapy. J Clin Oncol. 2018;36(15):3051\u20133051.",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Correlation of pre-CAR CD19 expression with responses and relapses after CAR T cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0030",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85050595660",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "15"
                                },
                                "pagerange": {"@first": "3051"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Pillai",
                                        "ce:indexed-name": "Pillai V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Rosenthal",
                                        "ce:indexed-name": "Rosenthal J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Muralidharan",
                                        "ce:indexed-name": "Muralidharan K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Pillai V, Rosenthal J, Muralidharan K, et al. Correlation of pre-CAR CD19 expression with responses and relapses after CAR T cell therapy. J Clin Oncol. 2018;36(15):3051\u20133051."
                    },
                    {
                        "ref-fulltext": "Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u201328.",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0031",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85040337972",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "20",
                                    "@last": "28"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Fry",
                                        "ce:indexed-name": "Fry T.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Shah",
                                        "ce:indexed-name": "Shah N.N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "R.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Orentas",
                                        "ce:indexed-name": "Orentas R.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u201328."
                    },
                    {
                        "ref-fulltext": "Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406\u20132410.",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0032",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84971641150",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "127",
                                    "@issue": "20"
                                },
                                "pagerange": {
                                    "@first": "2406",
                                    "@last": "2410"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Gardner",
                                        "ce:indexed-name": "Gardner R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Wu",
                                        "ce:indexed-name": "Wu D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Cherian",
                                        "ce:indexed-name": "Cherian S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406\u20132410."
                    },
                    {
                        "ref-fulltext": "Reiss DJ, Do T, Kuo D, et al. Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel) in transcend NHL 001 reveal patterns of immune infiltration associated with durable response. Blood. 2019;134(1):202\u2013202.",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel) in transcend NHL 001 reveal patterns of immune infiltration associated with durable response"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0033",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85087009032",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "202"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Reiss",
                                        "ce:indexed-name": "Reiss D.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Do",
                                        "ce:indexed-name": "Do T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Kuo",
                                        "ce:indexed-name": "Kuo D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Reiss DJ, Do T, Kuo D, et al. Multiplexed immunofluorescence (IF) analysis and gene expression profiling of biopsies from patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel) in transcend NHL 001 reveal patterns of immune infiltration associated with durable response. Blood. 2019;134(1):202\u2013202."
                    },
                    {
                        "ref-fulltext": "Yan ZX, Li L, Wang W, et al. Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin\u2019s lymphoma. Clin Cancer Res. 2019;25(23):6995\u20137003.",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin\u2019s lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0034",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075958120",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "23"
                                },
                                "pagerange": {
                                    "@first": "6995",
                                    "@last": "7003"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Z.X.",
                                        "@_fa": "true",
                                        "ce:surname": "Yan",
                                        "ce:indexed-name": "Yan Z.X."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Yan ZX, Li L, Wang W, et al. Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin\u2019s lymphoma. Clin Cancer Res. 2019;25(23):6995\u20137003."
                    },
                    {
                        "ref-fulltext": "Curran KJ, Margossian S, Kernan NA, et al. Conditioning prior to CAR T cells predicts response and survival in pediatric/young adult relapse/refractory (R/R) B-ALL. Biol Blood Marrow Transplant. 2019;25(3):S170.",
                        "@id": "35",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Conditioning prior to CAR T cells predicts response and survival in pediatric/young adult relapse/refractory (R/R) B-ALL"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0035",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85087038586",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "S170"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Curran",
                                        "ce:indexed-name": "Curran K.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Margossian",
                                        "ce:indexed-name": "Margossian S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Kernan",
                                        "ce:indexed-name": "Kernan N.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Curran KJ, Margossian S, Kernan NA, et al. Conditioning prior to CAR T cells predicts response and survival in pediatric/young adult relapse/refractory (R/R) B-ALL. Biol Blood Marrow Transplant. 2019;25(3):S170."
                    },
                    {
                        "ref-fulltext": "Turtle CJ, Hanafi LA, Berger C, et al. Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia. Blood. 2015;126(23):3773\u20133773.",
                        "@id": "36",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0036",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84966299113",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "126",
                                    "@issue": "23"
                                },
                                "pagerange": {"@first": "3773"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Turtle",
                                        "ce:indexed-name": "Turtle C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Berger",
                                        "ce:indexed-name": "Berger C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Turtle CJ, Hanafi LA, Berger C, et al. Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia. Blood. 2015;126(23):3773\u20133773."
                    },
                    {
                        "ref-fulltext": "Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116\u2013355ra116.",
                        "@id": "37",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0037",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84988805188",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "355"
                                },
                                "pagerange": {"@first": "355ra116"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Turtle",
                                        "ce:indexed-name": "Turtle C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Berger",
                                        "ce:indexed-name": "Berger C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116\u2013355ra116."
                    },
                    {
                        "ref-fulltext": "Westin JR, Tam CS, Borchmann P, et al. Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the Juliet trial. Blood. 2019;134(1):4103\u20134103.",
                        "@id": "38",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the Juliet trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0038",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85085284365",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "4103"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Westin",
                                        "ce:indexed-name": "Westin J.R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tam",
                                        "ce:indexed-name": "Tam C.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Borchmann",
                                        "ce:indexed-name": "Borchmann P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Westin JR, Tam CS, Borchmann P, et al. Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the Juliet trial. Blood. 2019;134(1):4103\u20134103."
                    },
                    {
                        "ref-fulltext": "Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492\u2013500.",
                        "@id": "39",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0039",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84959328185",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "30",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "492",
                                    "@last": "500"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Sommermeyer",
                                        "ce:indexed-name": "Sommermeyer D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Hudecek",
                                        "ce:indexed-name": "Hudecek M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Kosasih",
                                        "ce:indexed-name": "Kosasih P.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leukemia"
                        },
                        "ce:source-text": "Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492\u2013500."
                    },
                    {
                        "ref-fulltext": "Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u20132138.",
                        "@id": "40",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0040",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84974555520",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "126",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "2123",
                                    "@last": "2138"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Turtle",
                                        "ce:indexed-name": "Turtle C.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Hanafi",
                                        "ce:indexed-name": "Hanafi L.A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Berger",
                                        "ce:indexed-name": "Berger C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Invest"
                        },
                        "ce:source-text": "Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123\u20132138."
                    },
                    {
                        "ref-fulltext": "Porter DL, Frey NV, Melenhorst JJ, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed. Refractory CLL Blood. 2014;124(21):1982\u20131982.",
                        "@id": "41",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0041",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84927768738",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "124",
                                    "@issue": "21"
                                },
                                "pagerange": {"@first": "1982"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Porter",
                                        "ce:indexed-name": "Porter D.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Frey",
                                        "ce:indexed-name": "Frey N.V."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Melenhorst",
                                        "ce:indexed-name": "Melenhorst J.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Refractory CLL Blood"
                        },
                        "ce:source-text": "Porter DL, Frey NV, Melenhorst JJ, et al. Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed. Refractory CLL Blood. 2014;124(21):1982\u20131982."
                    },
                    {
                        "ref-fulltext": "Pan J, Yang JF, Deng BP, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017;31(12):2587\u20132593.",
                        "@id": "42",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0042",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85036628640",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "31",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "2587",
                                    "@last": "2593"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Pan",
                                        "ce:indexed-name": "Pan J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Yang",
                                        "ce:indexed-name": "Yang J.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Deng",
                                        "ce:indexed-name": "Deng B.P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Leukemia"
                        },
                        "ce:source-text": "Pan J, Yang JF, Deng BP, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017;31(12):2587\u20132593."
                    },
                    {
                        "ref-fulltext": "Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u2013549.",
                        "@id": "43",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2015"},
                            "ref-title": {"ref-titletext": "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0043",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84923118622",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "33",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "540",
                                    "@last": "549"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Kochenderfer",
                                        "ce:indexed-name": "Kochenderfer J.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Dudley",
                                        "ce:indexed-name": "Dudley M.E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Kassim",
                                        "ce:indexed-name": "Kassim S.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u2013549."
                    },
                    {
                        "ref-fulltext": "Abramson JS, Siddiqi T, Palomba ML, et al. High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration. J Clin Oncol. 2018;36(5):120\u2013120.",
                        "@id": "44",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0044",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85057483605",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "36",
                                    "@issue": "5"
                                },
                                "pagerange": {"@first": "120"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Abramson",
                                        "ce:indexed-name": "Abramson J.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Siddiqi",
                                        "ce:indexed-name": "Siddiqi T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Palomba",
                                        "ce:indexed-name": "Palomba M.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Abramson JS, Siddiqi T, Palomba ML, et al. High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration. J Clin Oncol. 2018;36(5):120\u2013120."
                    },
                    {
                        "ref-fulltext": "Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u20131737.",
                        "@id": "45",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0045",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85065137503",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "380",
                                    "@issue": "18"
                                },
                                "pagerange": {
                                    "@first": "1726",
                                    "@last": "1737"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Raje",
                                        "ce:indexed-name": "Raje N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Berdeja",
                                        "ce:indexed-name": "Berdeja J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Lin",
                                        "ce:indexed-name": "Lin Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u20131737."
                    },
                    {
                        "ref-fulltext": "Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.",
                        "@id": "46",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0046",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058893984",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "11",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "141"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "W.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhao",
                                        "ce:indexed-name": "Zhao W.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Liu",
                                        "ce:indexed-name": "Liu J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang B.Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Hematol Oncol"
                        },
                        "ce:source-text": "Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141."
                    },
                    {
                        "ref-fulltext": "Mailankody S, Htut M, Lee KP, et al. JCARH125, Anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE). Blood. 2018;132(1):957\u2013957.",
                        "@id": "47",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "JCARH125, Anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0047",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85062369142",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "132",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "957"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Mailankody",
                                        "ce:indexed-name": "Mailankody S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Htut",
                                        "ce:indexed-name": "Htut M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.P.",
                                        "@_fa": "true",
                                        "ce:surname": "Lee",
                                        "ce:indexed-name": "Lee K.P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Mailankody S, Htut M, Lee KP, et al. JCARH125, Anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE). Blood. 2018;132(1):957\u2013957."
                    },
                    {
                        "ref-fulltext": "Kravets VG, Zhang Y, Sun H. Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy. J Immunol Res Ther. 2017;2(1):100\u2013113.",
                        "@id": "48",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0048",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85087003685",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "2",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "100",
                                    "@last": "113"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "V.G.",
                                    "@_fa": "true",
                                    "ce:surname": "Kravets",
                                    "ce:indexed-name": "Kravets V.G."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "Y.",
                                    "@_fa": "true",
                                    "ce:surname": "Zhang",
                                    "ce:indexed-name": "Zhang Y."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "H.",
                                    "@_fa": "true",
                                    "ce:surname": "Sun",
                                    "ce:indexed-name": "Sun H."
                                }
                            ]},
                            "ref-sourcetitle": "J Immunol Res Ther"
                        },
                        "ce:source-text": "Kravets VG, Zhang Y, Sun H. Chimeric-antigen-receptor (CAR) T cells and the factors influencing their therapeutic efficacy. J Immunol Res Ther. 2017;2(1):100\u2013113."
                    },
                    {
                        "ref-fulltext": "Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290\u20131297.",
                        "@id": "49",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "A human memory T cell subset with stem cell-like properties"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0049",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "80053997259",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "17",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "1290",
                                    "@last": "1297"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Gattinoni",
                                        "ce:indexed-name": "Gattinoni L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Lugli",
                                        "ce:indexed-name": "Lugli E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Ji",
                                        "ce:indexed-name": "Ji Y."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290\u20131297."
                    },
                    {
                        "ref-fulltext": "Lugli E, Dominguez MH, Gattinoni L, et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest. 2013;123(2):594\u2013599.",
                        "@id": "50",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2013"},
                            "ref-title": {"ref-titletext": "Superior T memory stem cell persistence supports long-lived T cell memory"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0050",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84873395620",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "123",
                                    "@issue": "2"
                                },
                                "pagerange": {
                                    "@first": "594",
                                    "@last": "599"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Lugli",
                                        "ce:indexed-name": "Lugli E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Dominguez",
                                        "ce:indexed-name": "Dominguez M.H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Gattinoni",
                                        "ce:indexed-name": "Gattinoni L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Invest"
                        },
                        "ce:source-text": "Lugli E, Dominguez MH, Gattinoni L, et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest. 2013;123(2):594\u2013599."
                    },
                    {
                        "ref-fulltext": "Wang X, Popplewell LL, Wagner JR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127(24):2980\u20132990.",
                        "@id": "51",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0051",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84976333265",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "127",
                                    "@issue": "24"
                                },
                                "pagerange": {
                                    "@first": "2980",
                                    "@last": "2990"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang X."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "L.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Popplewell",
                                        "ce:indexed-name": "Popplewell L.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Wagner",
                                        "ce:indexed-name": "Wagner J.R."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Wang X, Popplewell LL, Wagner JR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127(24):2980\u20132990."
                    },
                    {
                        "ref-fulltext": "Singh N, Perazzelli J, Grupp SA, et al. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8(320):320ra3\u2013320ra3.",
                        "@id": "52",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0052",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84954566107",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "320"
                                },
                                "pagerange": {"@first": "320ra3"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Singh",
                                        "ce:indexed-name": "Singh N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Perazzelli",
                                        "ce:indexed-name": "Perazzelli J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Grupp",
                                        "ce:indexed-name": "Grupp S.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Transl Med"
                        },
                        "ce:source-text": "Singh N, Perazzelli J, Grupp SA, et al. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8(320):320ra3\u2013320ra3."
                    },
                    {
                        "ref-fulltext": "Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750\u20133759.",
                        "@id": "53",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0053",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84902590274",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "123",
                                    "@issue": "24"
                                },
                                "pagerange": {
                                    "@first": "3750",
                                    "@last": "3759"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu Y."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Zhang",
                                        "ce:indexed-name": "Zhang M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Ramos",
                                        "ce:indexed-name": "Ramos C.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750\u20133759."
                    },
                    {
                        "ref-fulltext": "Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u2013571.",
                        "@id": "54",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0054",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85046093409",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "563",
                                    "@last": "571"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Fraietta",
                                        "ce:indexed-name": "Fraietta J.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Lacey",
                                        "ce:indexed-name": "Lacey S.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Orlando",
                                        "ce:indexed-name": "Orlando E.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u2013571."
                    },
                    {
                        "ref-fulltext": "Finney OC, Brakke HM, Rawlings-Rhea S, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129(5):2123\u20132132.",
                        "@id": "55",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "CD19 CAR T cell product and disease attributes predict leukemia remission durability"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0055",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85062816323",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "129",
                                    "@issue": "5"
                                },
                                "pagerange": {
                                    "@first": "2123",
                                    "@last": "2132"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Finney",
                                        "ce:indexed-name": "Finney O.C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Brakke",
                                        "ce:indexed-name": "Brakke H.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.",
                                        "@_fa": "true",
                                        "ce:surname": "Rawlings-Rhea",
                                        "ce:indexed-name": "Rawlings-Rhea S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Invest"
                        },
                        "ce:source-text": "Finney OC, Brakke HM, Rawlings-Rhea S, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129(5):2123\u20132132."
                    },
                    {
                        "ref-fulltext": "Beider K, Besser MJ, Schachter J, et al. Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies. Blood. 2019;134(1):3234\u20133234.",
                        "@id": "56",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0056",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85084973048",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "3234"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Beider",
                                        "ce:indexed-name": "Beider K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Besser",
                                        "ce:indexed-name": "Besser M.J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Schachter",
                                        "ce:indexed-name": "Schachter J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Beider K, Besser MJ, Schachter J, et al. Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies. Blood. 2019;134(1):3234\u20133234."
                    },
                    {
                        "ref-fulltext": "Worel N, Pfistershammer K, Pickl W, et al. Influence of CD27- CD28- T-cells on the therapeutic outcome in adult patients with relapsed or refractory diffuse large B-cell lymphoma after CART-infusion. Blood. 2019;134(1):1935\u20131935.",
                        "@id": "57",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Influence of CD27- CD28- T-cells on the therapeutic outcome in adult patients with relapsed or refractory diffuse large B-cell lymphoma after CART-infusion"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0057",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85087005086",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "1935"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Worel",
                                        "ce:indexed-name": "Worel N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Pfistershammer",
                                        "ce:indexed-name": "Pfistershammer K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "W.",
                                        "@_fa": "true",
                                        "ce:surname": "Pickl",
                                        "ce:indexed-name": "Pickl W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Worel N, Pfistershammer K, Pickl W, et al. Influence of CD27- CD28- T-cells on the therapeutic outcome in adult patients with relapsed or refractory diffuse large B-cell lymphoma after CART-infusion. Blood. 2019;134(1):1935\u20131935."
                    },
                    {
                        "ref-fulltext": "Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (Basel). 2016;8(3):36.",
                        "@id": "58",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0058",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84962538959",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "8",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "36"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "V.",
                                    "@_fa": "true",
                                    "ce:surname": "Golubovskaya",
                                    "ce:indexed-name": "Golubovskaya V."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "L.",
                                    "@_fa": "true",
                                    "ce:surname": "Wu",
                                    "ce:indexed-name": "Wu L."
                                }
                            ]},
                            "ref-sourcetitle": "Cancers (Basel"
                        },
                        "ce:source-text": "Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers (Basel). 2016;8(3):36."
                    },
                    {
                        "ref-fulltext": "Bachanova V, Tam CS, Borchmann P, et al. Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-Cell lymphoma (R/R DLBCL). Blood. 2019;134(1):242\u2013242.",
                        "@id": "59",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-Cell lymphoma (R/R DLBCL)"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0059",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85085767361",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "242"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "Bachanova",
                                        "ce:indexed-name": "Bachanova V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Tam",
                                        "ce:indexed-name": "Tam C.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Borchmann",
                                        "ce:indexed-name": "Borchmann P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Bachanova V, Tam CS, Borchmann P, et al. Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-Cell lymphoma (R/R DLBCL). Blood. 2019;134(1):242\u2013242."
                    },
                    {
                        "ref-fulltext": "Sauter CS, Senechal B, Riviere I, et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019;134(7):626\u2013635.",
                        "@id": "60",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0060",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85070782684",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "134",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "626",
                                    "@last": "635"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Sauter",
                                        "ce:indexed-name": "Sauter C.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Senechal",
                                        "ce:indexed-name": "Senechal B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Riviere",
                                        "ce:indexed-name": "Riviere I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Sauter CS, Senechal B, Riviere I, et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019;134(7):626\u2013635."
                    },
                    {
                        "ref-fulltext": "Davila ML. CAR T cells find strength in polyfunction. Blood. 2018;132(8):769\u2013770.",
                        "@id": "61",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "CAR T cells find strength in polyfunction"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0061",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052077886",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "132",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "769",
                                    "@last": "770"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "M.L.",
                                "@_fa": "true",
                                "ce:surname": "Davila",
                                "ce:indexed-name": "Davila M.L."
                            }]},
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Davila ML. CAR T cells find strength in polyfunction. Blood. 2018;132(8):769\u2013770."
                    },
                    {
                        "ref-fulltext": "Rossi J, Paczkowski P, Shen YW, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132(8):804\u2013814.",
                        "@id": "62",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0062",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052110726",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "132",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "804",
                                    "@last": "814"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Rossi",
                                        "ce:indexed-name": "Rossi J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Paczkowski",
                                        "ce:indexed-name": "Paczkowski P."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "Y.W.",
                                        "@_fa": "true",
                                        "ce:surname": "Shen",
                                        "ce:indexed-name": "Shen Y.W."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Rossi J, Paczkowski P, Shen YW, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132(8):804\u2013814."
                    },
                    {
                        "ref-fulltext": "Kawalekar OU, O\u2019 Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(3):712.",
                        "@id": "63",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0063",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84960374081",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "44",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "712"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "O.U.",
                                        "@_fa": "true",
                                        "ce:surname": "Kawalekar",
                                        "ce:indexed-name": "Kawalekar O.U."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.S.",
                                        "@_fa": "true",
                                        "ce:surname": "O\u2019 Connor",
                                        "ce:indexed-name": "O' Connor R.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Fraietta",
                                        "ce:indexed-name": "Fraietta J.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Immunity"
                        },
                        "ce:source-text": "Kawalekar OU, O\u2019 Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(3):712."
                    },
                    {
                        "ref-fulltext": "Salter AI, Ivey RG, Kennedy JJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11(544):eaat6753.",
                        "@id": "64",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0064",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85052106164",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "11",
                                    "@issue": "544"
                                },
                                "pagerange": {"@first": "eaat6753"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.I.",
                                        "@_fa": "true",
                                        "ce:surname": "Salter",
                                        "ce:indexed-name": "Salter A.I."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.G.",
                                        "@_fa": "true",
                                        "ce:surname": "Ivey",
                                        "ce:indexed-name": "Ivey R.G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Kennedy",
                                        "ce:indexed-name": "Kennedy J.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Sci Signal"
                        },
                        "ce:source-text": "Salter AI, Ivey RG, Kennedy JJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11(544):eaat6753."
                    },
                    {
                        "ref-fulltext": "Ying Z, He T, Wang X, et al. Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma. Mol Ther Oncol. 2019;15:60\u201368.",
                        "@id": "65",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0065",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85073033273",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "15"},
                                "pagerange": {
                                    "@first": "60",
                                    "@last": "68"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "Z.",
                                        "@_fa": "true",
                                        "ce:surname": "Ying",
                                        "ce:indexed-name": "Ying Z."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "He",
                                        "ce:indexed-name": "He T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Wang",
                                        "ce:indexed-name": "Wang X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Mol Ther Oncol"
                        },
                        "ce:source-text": "Ying Z, He T, Wang X, et al. Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma. Mol Ther Oncol. 2019;15:60\u201368."
                    },
                    {
                        "ref-fulltext": "Milone MC, Bhoj VG. The pharmacology of T cell therapies. Mol Ther Methods Clin Dev. 2018;8:210\u2013221.",
                        "@id": "66",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "The pharmacology of T cell therapies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0066",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85043517162",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "8"},
                                "pagerange": {
                                    "@first": "210",
                                    "@last": "221"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "M.C.",
                                    "@_fa": "true",
                                    "ce:surname": "Milone",
                                    "ce:indexed-name": "Milone M.C."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "V.G.",
                                    "@_fa": "true",
                                    "ce:surname": "Bhoj",
                                    "ce:indexed-name": "Bhoj V.G."
                                }
                            ]},
                            "ref-sourcetitle": "Mol Ther Methods Clin Dev"
                        },
                        "ce:source-text": "Milone MC, Bhoj VG. The pharmacology of T cell therapies. Mol Ther Methods Clin Dev. 2018;8:210\u2013221."
                    },
                    {
                        "ref-fulltext": "Mueller KT, Maude SL, Porter DL, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130(21):2317\u20132325.",
                        "@id": "67",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0067",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85034844703",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "130",
                                    "@issue": "21"
                                },
                                "pagerange": {
                                    "@first": "2317",
                                    "@last": "2325"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Mueller",
                                        "ce:indexed-name": "Mueller K.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Maude",
                                        "ce:indexed-name": "Maude S.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Porter",
                                        "ce:indexed-name": "Porter D.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Mueller KT, Maude SL, Porter DL, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130(21):2317\u20132325."
                    },
                    {
                        "ref-fulltext": "Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u2013733.",
                        "@id": "68",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0068",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "80051720194",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "365",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "725",
                                    "@last": "733"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Porter",
                                        "ce:indexed-name": "Porter D.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Levine",
                                        "ce:indexed-name": "Levine B.L."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Kalos",
                                        "ce:indexed-name": "Kalos M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "N Engl J Med"
                        },
                        "ce:source-text": "Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u2013733."
                    },
                    {
                        "ref-fulltext": "Mueller KT, Waldron E, Grupp SA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24(24):6175\u20136184.",
                        "@id": "69",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0069",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058453793",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "24"
                                },
                                "pagerange": {
                                    "@first": "6175",
                                    "@last": "6184"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Mueller",
                                        "ce:indexed-name": "Mueller K.T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Waldron",
                                        "ce:indexed-name": "Waldron E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Grupp",
                                        "ce:indexed-name": "Grupp S.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Mueller KT, Waldron E, Grupp SA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24(24):6175\u20136184."
                    },
                    {
                        "ref-fulltext": "Geyer MB, Riviere I, Senechal B, et al. Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. Mol Ther. 2018;26(8):1896\u20131905.",
                        "@id": "70",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0070",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85048545983",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "26",
                                    "@issue": "8"
                                },
                                "pagerange": {
                                    "@first": "1896",
                                    "@last": "1905"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.B.",
                                        "@_fa": "true",
                                        "ce:surname": "Geyer",
                                        "ce:indexed-name": "Geyer M.B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Riviere",
                                        "ce:indexed-name": "Riviere I."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Senechal",
                                        "ce:indexed-name": "Senechal B."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Mol Ther"
                        },
                        "ce:source-text": "Geyer MB, Riviere I, Senechal B, et al. Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. Mol Ther. 2018;26(8):1896\u20131905."
                    },
                    {
                        "ref-fulltext": "Kochenderfer JN, Somerville RPT, Lu T, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25(10):2245\u20132253.",
                        "@id": "71",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0071",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85028330613",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "2245",
                                    "@last": "2253"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Kochenderfer",
                                        "ce:indexed-name": "Kochenderfer J.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.P.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Somerville",
                                        "ce:indexed-name": "Somerville R.P.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Mol Ther"
                        },
                        "ce:source-text": "Kochenderfer JN, Somerville RPT, Lu T, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25(10):2245\u20132253."
                    },
                    {
                        "ref-fulltext": "Xu X, Sun Q, Liang X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664.",
                        "@id": "72",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0072",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85076045562",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "10"},
                                "pagerange": {"@first": "2664"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Xu",
                                        "ce:indexed-name": "Xu X."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Q.",
                                        "@_fa": "true",
                                        "ce:surname": "Sun",
                                        "ce:indexed-name": "Sun Q."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Liang",
                                        "ce:indexed-name": "Liang X."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Front Immunol"
                        },
                        "ce:source-text": "Xu X, Sun Q, Liang X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664."
                    },
                    {
                        "ref-fulltext": "Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504\u20131506.",
                        "@id": "73",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0073",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85054482344",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "10"
                                },
                                "pagerange": {
                                    "@first": "1504",
                                    "@last": "1506"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Orlando",
                                        "ce:indexed-name": "Orlando E.J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "X.",
                                        "@_fa": "true",
                                        "ce:surname": "Han",
                                        "ce:indexed-name": "Han X."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Tribouley",
                                        "ce:indexed-name": "Tribouley C."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Nat Med"
                        },
                        "ce:source-text": "Orlando EJ, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504\u20131506."
                    },
                    {
                        "ref-fulltext": "Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016;127(26):3312\u20133320.",
                        "@id": "74",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0074",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84977489592",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "127",
                                    "@issue": "26"
                                },
                                "pagerange": {
                                    "@first": "3312",
                                    "@last": "3320"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.H.",
                                    "@_fa": "true",
                                    "ce:surname": "Park",
                                    "ce:indexed-name": "Park J.H."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "M.B.",
                                    "@_fa": "true",
                                    "ce:surname": "Geyer",
                                    "ce:indexed-name": "Geyer M.B."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "R.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Brentjens",
                                    "ce:indexed-name": "Brentjens R.J."
                                }
                            ]},
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016;127(26):3312\u20133320."
                    },
                    {
                        "ref-fulltext": "Garfall AL, Dancy EK, Cohen AD, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812\u20132815.",
                        "@id": "75",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0075",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85073423205",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "3",
                                    "@issue": "19"
                                },
                                "pagerange": {
                                    "@first": "2812",
                                    "@last": "2815"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "A.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Garfall",
                                        "ce:indexed-name": "Garfall A.L."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.K.",
                                        "@_fa": "true",
                                        "ce:surname": "Dancy",
                                        "ce:indexed-name": "Dancy E.K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.D.",
                                        "@_fa": "true",
                                        "ce:surname": "Cohen",
                                        "ce:indexed-name": "Cohen A.D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood Adv"
                        },
                        "ce:source-text": "Garfall AL, Dancy EK, Cohen AD, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3(19):2812\u20132815."
                    },
                    {
                        "ref-fulltext": "Perica K, Flynn J, Curran KJ, et al. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL. J Clin Oncol. 2019;37(15):2520\u20132520.",
                        "@id": "76",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0076",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075433867",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "37",
                                    "@issue": "15"
                                },
                                "pagerange": {"@first": "2520"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Perica",
                                        "ce:indexed-name": "Perica K."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Flynn",
                                        "ce:indexed-name": "Flynn J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Curran",
                                        "ce:indexed-name": "Curran K.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Perica K, Flynn J, Curran KJ, et al. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL. J Clin Oncol. 2019;37(15):2520\u20132520."
                    },
                    {
                        "ref-fulltext": "Qu C, Ping N, Kang L, et al. Radiation priming chimeric antigen receptor T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma with high tumor burden. J Immunother. 2020;43(1):32\u201337.",
                        "@id": "77",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Radiation priming chimeric antigen receptor T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma with high tumor burden"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0077",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85068422360",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "43",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "32",
                                    "@last": "37"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Qu",
                                        "ce:indexed-name": "Qu C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Ping",
                                        "ce:indexed-name": "Ping N."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "L.",
                                        "@_fa": "true",
                                        "ce:surname": "Kang",
                                        "ce:indexed-name": "Kang L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Immunother"
                        },
                        "ce:source-text": "Qu C, Ping N, Kang L, et al. Radiation priming chimeric antigen receptor T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma with high tumor burden. J Immunother. 2020;43(1):32\u201337."
                    },
                    {
                        "ref-fulltext": "Fraietta JA, Lacey SF, Wilcox NS, et al. Biomarkers of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with chronic lymphocytic leukemia. Blood. 2016;128(22):57\u201357.",
                        "@id": "78",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "ref-title": {"ref-titletext": "Biomarkers of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with chronic lymphocytic leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0078",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85043520983",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "128",
                                    "@issue": "22"
                                },
                                "pagerange": {"@first": "57"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Fraietta",
                                        "ce:indexed-name": "Fraietta J.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "S.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Lacey",
                                        "ce:indexed-name": "Lacey S.F."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Wilcox",
                                        "ce:indexed-name": "Wilcox N.S."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Fraietta JA, Lacey SF, Wilcox NS, et al. Biomarkers of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with chronic lymphocytic leukemia. Blood. 2016;128(22):57\u201357."
                    },
                    {
                        "ref-fulltext": "Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u20131813.",
                        "@id": "79",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0079",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85017643829",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "35",
                                    "@issue": "16"
                                },
                                "pagerange": {
                                    "@first": "1803",
                                    "@last": "1813"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.N.",
                                        "@_fa": "true",
                                        "ce:surname": "Kochenderfer",
                                        "ce:indexed-name": "Kochenderfer J.N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.P.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Somerville",
                                        "ce:indexed-name": "Somerville R.P.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Lu",
                                        "ce:indexed-name": "Lu T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Clin Oncol"
                        },
                        "ce:source-text": "Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u20131813."
                    },
                    {
                        "ref-fulltext": "Enblad G, Karlsson H, Gammelgård G, et al. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24(24):6185\u20136194.",
                        "@id": "80",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0080",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85058453077",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "24"
                                },
                                "pagerange": {
                                    "@first": "6185",
                                    "@last": "6194"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Enblad",
                                        "ce:indexed-name": "Enblad G."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Karlsson",
                                        "ce:indexed-name": "Karlsson H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Gammelgård",
                                        "ce:indexed-name": "Gammelgard G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Cancer Res"
                        },
                        "ce:source-text": "Enblad G, Karlsson H, Gammelgård G, et al. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24(24):6185\u20136194."
                    },
                    {
                        "ref-fulltext": "Siddiqi T, Abramson JS, Li D, et al. Patient characteristics and pre-infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19-targeted CAR T cell product. Blood. 2017;130(1):193.",
                        "@id": "81",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Patient characteristics and pre-infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19-targeted CAR T cell product"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0081",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85065161396",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "130",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "193"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Siddiqi",
                                        "ce:indexed-name": "Siddiqi T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Abramson",
                                        "ce:indexed-name": "Abramson J.S."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Li",
                                        "ce:indexed-name": "Li D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Blood"
                        },
                        "ce:source-text": "Siddiqi T, Abramson JS, Li D, et al. Patient characteristics and pre-infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19-targeted CAR T cell product. Blood. 2017;130(1):193."
                    },
                    {
                        "ref-fulltext": "Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019;7(1):108.",
                        "@id": "82",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Exploring the emerging role of the microbiome in cancer immunotherapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0082",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85064465557",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "1"
                                },
                                "pagerange": {"@first": "108"}
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "J.",
                                    "@_fa": "true",
                                    "ce:surname": "Fessler",
                                    "ce:indexed-name": "Fessler J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "V.",
                                    "@_fa": "true",
                                    "ce:surname": "Matson",
                                    "ce:indexed-name": "Matson V."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "T.F.",
                                    "@_fa": "true",
                                    "ce:surname": "Gajewski",
                                    "ce:indexed-name": "Gajewski T.F."
                                }
                            ]},
                            "ref-sourcetitle": "J Immunother Cancer"
                        },
                        "ce:source-text": "Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019;7(1):108."
                    },
                    {
                        "ref-fulltext": "Shaikh FY, Gills JJ, Sears CL. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma. EBioMedicine. 2019;48:642\u2013647.",
                        "@id": "83",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0083",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85072836491",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "48"},
                                "pagerange": {
                                    "@first": "642",
                                    "@last": "647"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "F.Y.",
                                    "@_fa": "true",
                                    "ce:surname": "Shaikh",
                                    "ce:indexed-name": "Shaikh F.Y."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "J.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Gills",
                                    "ce:indexed-name": "Gills J.J."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "C.L.",
                                    "@_fa": "true",
                                    "ce:surname": "Sears",
                                    "ce:indexed-name": "Sears C.L."
                                }
                            ]},
                            "ref-sourcetitle": "EBioMedicine"
                        },
                        "ce:source-text": "Shaikh FY, Gills JJ, Sears CL. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma. EBioMedicine. 2019;48:642\u2013647."
                    },
                    {
                        "ref-fulltext": "Smith M, Littmann E, Slingerland J, et al. Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy. Biol Blood Marrow Transplant. 2019;25(3):S177.",
                        "@id": "84",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "CIT0084",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85075843190",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "25",
                                    "@issue": "3"
                                },
                                "pagerange": {"@first": "S177"}
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Littmann",
                                        "ce:indexed-name": "Littmann E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Slingerland",
                                        "ce:indexed-name": "Slingerland J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Biol Blood Marrow Transplant"
                        },
                        "ce:source-text": "Smith M, Littmann E, Slingerland J, et al. Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy. Biol Blood Marrow Transplant. 2019;25(3):S177."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "New York",
            "@id": "108088405",
            "affilname": "Cornell College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/108088405",
            "affiliation-country": "United States"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85087032230",
        "dc:description": "Over the past recent years, CD19-targeted chimeric antigen receptor T (CAR T) cell has transformed the treatment of relapsed/refractory (R/R) B lymphoid hematologic malignancy. CAR T cell therapy elicits an excellent anti-tumor effect and extends long-term disease-free remission in these difficult-to-treat patients. Notwithstanding, despite the impressive anti-tumor efficacy, some patients fail to attain clinical response or relapse after extended follow-up. The success of CAR T cell therapy involves complex interplays between host, tumor, and CAR T cell-associated arrays. Researchers have extensively explored potential predictive biomarkers for response to CAR T cell therapy. Ability to identify clinical and biological factors associated with improved response will help determine appropriate patients for CAR T cell treatment and enhance the clinical outcome of this novel therapeutic approach.",
        "pubmed-id": "32522059",
        "prism:coverDate": "2020-08-23",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85087032230",
        "dc:creator": {"author": [{
            "ce:given-name": "Kitsada",
            "preferred-name": {
                "ce:given-name": "Kitsada",
                "ce:initials": "K.",
                "ce:surname": "Wudhikarn",
                "ce:indexed-name": "Wudhikarn K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60028190",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
                }
            ],
            "ce:surname": "Wudhikarn",
            "@auid": "37091810400",
            "author-url": "https://api.elsevier.com/content/author/author_id/37091810400",
            "ce:indexed-name": "Wudhikarn K."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85087032230"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087032230&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85087032230&origin=inward"
            }
        ],
        "source-id": "26016",
        "citedby-count": "6",
        "prism:volume": "61",
        "subtype": "re",
        "dc:title": "Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice",
        "openaccess": "0",
        "prism:issn": "10292403 10428194",
        "publishercopyright": "© 2020 Informa UK Limited, trading as Taylor & Francis Group.",
        "prism:issueIdentifier": "10",
        "subtypeDescription": "Review",
        "prism:publicationName": "Leukemia and Lymphoma",
        "prism:pageRange": "2324-2334",
        "prism:endingPage": "2334",
        "openaccessFlag": "false",
        "prism:doi": "10.1080/10428194.2020.1761967",
        "prism:startingPage": "2324",
        "dc:identifier": "SCOPUS_ID:85087032230",
        "dc:publisher": "Taylor and Francis Ltd.michael.wagreich@univie.ac.at"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Antigens, CD19",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Hematologic Neoplasms",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Immunotherapy, Adoptive",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Neoplasm Recurrence, Local",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Receptors, Antigen, T-Cell",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Receptors, Chimeric Antigen",
            "@weight": "a",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "Chimeric antigen receptor T cell (CAR T cell)"
        },
        {
            "@_fa": "true",
            "$": "immunotherapy"
        },
        {
            "@_fa": "true",
            "$": "leukemia"
        },
        {
            "@_fa": "true",
            "$": "lymphoma"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ]},
    "authors": {"author": [
        {
            "ce:given-name": "Kitsada",
            "preferred-name": {
                "ce:given-name": "Kitsada",
                "ce:initials": "K.",
                "ce:surname": "Wudhikarn",
                "ce:indexed-name": "Wudhikarn K."
            },
            "@seq": "1",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "60028190",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"
                }
            ],
            "ce:surname": "Wudhikarn",
            "@auid": "37091810400",
            "author-url": "https://api.elsevier.com/content/author/author_id/37091810400",
            "ce:indexed-name": "Wudhikarn K."
        },
        {
            "ce:given-name": "Jae H.",
            "preferred-name": {
                "ce:given-name": "Jae H.",
                "ce:initials": "J.H.",
                "ce:surname": "Park",
                "ce:indexed-name": "Park J.H."
            },
            "@seq": "2",
            "ce:initials": "J.H.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60009343",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343"
                },
                {
                    "@id": "108088405",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/108088405"
                }
            ],
            "ce:surname": "Park",
            "@auid": "45561459900",
            "author-url": "https://api.elsevier.com/content/author/author_id/45561459900",
            "ce:indexed-name": "Park J.H."
        }
    ]}
}}